Investors & News

Latest News

Aug 06,2020
Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Jul 30,2020
Stealth BioTherapeutics to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Jun 17,2020
Stealth BioTherapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
All News

Stock Quote (MITO)

Share

Why invest?

Our Company

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.

Our Programs

We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.

Our Pipeline

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Latest Reports

August 06, 2020
Form 6-K : Report of Foreign Issuer
HTML
July 10, 2020
Form EFFECT : Effectiveness Order
HTML
Reports

Latest Presentations

August 06, 2020
Investor Presentation August 2020.
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
Presentations

Events

August 06, 2020
Stealth BioTherapeutics to Report Second Quarter 2020 Financial Results at 8:30am EST
Webcast
June 23, 2020
Stealth BioTherapeutics Fireside Chat: BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 3:00pm EST
Webcast
Financial Calendar
Media Relations

Amelia Stetler, 617-762-2562
media@stealthbt.com

Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com